A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management
<p>Hypomethylating drugs are useful and approved in the management of myelodysplastic syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). However, phase 2 and 3 studies that assessed these agents in MDS, have included only a small number of CMML, and there are only few specific...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2012-01-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/article/view/10013 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846098267428880384 |
|---|---|
| author | Elena Elli Caterina Cecchetti Angelo Belotti Lorenza Borin Enrico Maria Pogliani |
| author_facet | Elena Elli Caterina Cecchetti Angelo Belotti Lorenza Borin Enrico Maria Pogliani |
| author_sort | Elena Elli |
| collection | DOAJ |
| description | <p>Hypomethylating drugs are useful and approved in the management of myelodysplastic syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). However, phase 2 and 3 studies that assessed these agents in MDS, have included only a small number of CMML, and there are only few specific reports on CMML patients. Azacitidine is actually authorised for the treatment of CMML patients with 10-29% marrow blasts without myeloproliferative disorder who are not eligible for haematopoietic stem cell transplantation. This hypomethylating agent in MDS is known to cause transient cytopenias, most often occurring in the first 2 cycles. Here we report a case of atypical prolonged hematologic toxicity during azacitidine treatment in a CMML patient and we also review the literature regarding the efficacy of the drug and the management of hematologic adverse effects in specific CMML setting.</p> |
| format | Article |
| id | doaj-art-6afb8ba6899b48298ea15ff843f9ecd9 |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-6afb8ba6899b48298ea15ff843f9ecd92025-01-02T01:24:05ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062012-01-0141e2012017e2012017A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of managementElena ElliCaterina CecchettiAngelo BelottiLorenza BorinEnrico Maria Pogliani<p>Hypomethylating drugs are useful and approved in the management of myelodysplastic syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). However, phase 2 and 3 studies that assessed these agents in MDS, have included only a small number of CMML, and there are only few specific reports on CMML patients. Azacitidine is actually authorised for the treatment of CMML patients with 10-29% marrow blasts without myeloproliferative disorder who are not eligible for haematopoietic stem cell transplantation. This hypomethylating agent in MDS is known to cause transient cytopenias, most often occurring in the first 2 cycles. Here we report a case of atypical prolonged hematologic toxicity during azacitidine treatment in a CMML patient and we also review the literature regarding the efficacy of the drug and the management of hematologic adverse effects in specific CMML setting.</p>http://www.mjhid.org/article/view/10013Chronic myelomonocytic leukemiaazacitidinemyelodysplastic syndromesHematologic toxicity |
| spellingShingle | Elena Elli Caterina Cecchetti Angelo Belotti Lorenza Borin Enrico Maria Pogliani A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management Mediterranean Journal of Hematology and Infectious Diseases Chronic myelomonocytic leukemia azacitidine myelodysplastic syndromes Hematologic toxicity |
| title | A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management |
| title_full | A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management |
| title_fullStr | A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management |
| title_full_unstemmed | A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management |
| title_short | A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management |
| title_sort | case of atypical prolonged hematologic toxicity with azacitidine in chronic myelomonocytic leukemia cmml review of literature and a proposal of management |
| topic | Chronic myelomonocytic leukemia azacitidine myelodysplastic syndromes Hematologic toxicity |
| url | http://www.mjhid.org/article/view/10013 |
| work_keys_str_mv | AT elenaelli acaseofatypicalprolongedhematologictoxicitywithazacitidineinchronicmyelomonocyticleukemiacmmlreviewofliteratureandaproposalofmanagement AT caterinacecchetti acaseofatypicalprolongedhematologictoxicitywithazacitidineinchronicmyelomonocyticleukemiacmmlreviewofliteratureandaproposalofmanagement AT angelobelotti acaseofatypicalprolongedhematologictoxicitywithazacitidineinchronicmyelomonocyticleukemiacmmlreviewofliteratureandaproposalofmanagement AT lorenzaborin acaseofatypicalprolongedhematologictoxicitywithazacitidineinchronicmyelomonocyticleukemiacmmlreviewofliteratureandaproposalofmanagement AT enricomariapogliani acaseofatypicalprolongedhematologictoxicitywithazacitidineinchronicmyelomonocyticleukemiacmmlreviewofliteratureandaproposalofmanagement AT elenaelli caseofatypicalprolongedhematologictoxicitywithazacitidineinchronicmyelomonocyticleukemiacmmlreviewofliteratureandaproposalofmanagement AT caterinacecchetti caseofatypicalprolongedhematologictoxicitywithazacitidineinchronicmyelomonocyticleukemiacmmlreviewofliteratureandaproposalofmanagement AT angelobelotti caseofatypicalprolongedhematologictoxicitywithazacitidineinchronicmyelomonocyticleukemiacmmlreviewofliteratureandaproposalofmanagement AT lorenzaborin caseofatypicalprolongedhematologictoxicitywithazacitidineinchronicmyelomonocyticleukemiacmmlreviewofliteratureandaproposalofmanagement AT enricomariapogliani caseofatypicalprolongedhematologictoxicitywithazacitidineinchronicmyelomonocyticleukemiacmmlreviewofliteratureandaproposalofmanagement |